NAIP is a cytosolic pattern recognition receptor that functions as a sensor component of the NLRC4 inflammasome, a supramolecular complex assembled in response to intracellular bacterial infection. NAIP detects bacterial ligands including flagellin and components of type III secretion systems delivered by pathogens such as Salmonella and Legionella, triggering NLRC4 oligomerization and caspase-1 activation 1 2. This activation cascade promotes the proteolytic maturation of IL-1 family cytokines and induces pyroptosis, a form of inflammatory programmed cell death 3. Mechanistically, NAIP recognition of pathogen-associated molecules drives conformational changes that nucleate inflammasome assembly, recruiting and activating caspase-1 to execute downstream inflammatory responses 4. NAIP deletions occur in approximately 67% of severe (type I) spinal muscular atrophy cases, suggesting a role in motor neuron survival 5. Recent evidence indicates the NAIP/NLRC4 inflammasome contributes to inflammatory intestinal disease; targeting NAIP/NLRC4 activation by bacterial flagellin with small-molecule inhibitors like eugeniin showed promise in attenuating ulcerative colitis in mouse models 6. Human gain-of-function mutations in NLRC4 cause autoinflammatory syndromes with enterocolitis 2, highlighting the therapeutic potential of NAIP/NLRC4 inhibition in inflammatory disorders.